Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.10. | Chromocell announces amendment to stock repurchase plan | 1 | Seeking Alpha | ||
24.10. | Chromocell boosts stock buyback plan to $750,000 | 1 | Investing.com | ||
24.10. | Chromocell Therapeutics Corporation: Chromocell Announces Amendment to Stock Repurchase Plan | 1 | GlobeNewswire (USA) | ||
24.10. | Chromocell Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
16.09. | Chromocell therapeutics director buys $9.8k in stock | 1 | Investing.com | ||
16.09. | Chromocell therapeutics CEO buys $5,044 in company stock | 1 | Investing.com | ||
12.09. | Chromocell Therapeutics CEO buys shares worth over $10,000 | 1 | Investing.com | ||
13.08. | Chromocell Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
07.08. | Chromocell Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
07.08. | Chromocell announces stock repurchase plan | 1 | Seeking Alpha | ||
07.08. | Chromocell Therapeutics Corporation: Chromocell Announces Stock Repurchase Plan | 1 | GlobeNewswire (USA) | ||
29.07. | Chromocell Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
29.07. | Chromocell Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
15.07. | Chromocell Corporation: Chromocell to Participate in the Virtual Investor Lunch Break Series | 1 | GlobeNewswire (USA) | ||
13.05. | Chromocell Corporation: Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024 | 1 | GlobeNewswire (USA) | ||
17.04. | Pre-market Movers: INVO Bioscience, iLearningEngines, Vanda Pharmaceuticals, CXApp, Chromocell Therapeutics | 533 | AFX News | LOWELL (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.45 A.M. ET).In the Green INVO Bioscience, Inc. (INVO) is up over 73% at $1.35.
Vanda... ► Artikel lesen | |
09.04. | Chromocell Corporation: Chromocell Issues Letter to Stockholders from Chief Executive Officer | 281 | GlobeNewswire (Europe) | FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment... ► Artikel lesen | |
18.03. | Chromocell Corporation: Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 | 171 | GlobeNewswire (Europe) | FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment... ► Artikel lesen | |
21.02. | Chromocell Corporation: Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million | 227 | GlobeNewswire (Europe) | FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) ("Chromocell", "our", "us" or the "Company"), a clinical-stage biotech company focused on... ► Artikel lesen | |
16.02. | Chromocell Therapeutics Announces Pricing Of $6.6 Mln Initial Public Offering | 579 | AFX News | WASHINGTON (dpa-AFX) - Chromocell Therapeutics Corp. (CHRO) announced the pricing of its initial public offering of 1,100,000 shares of common stock at $6.00 per share on Friday. This offering... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,200 | -15,29 % | BASF, Deutsche Bank, Evotec, Nel ASA, Steyr Motors, Volkswagen - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
QIAGEN | 40,100 | +0,40 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Meningitis/ Enzephalitis-Panel zur Unterstützung der Notfalldiagnostik | QIAstat-Dx Meningitis/Enzephalitis-Panel in den USA für den klinischen Einsatz zugelassen, um Diagnosen von Infektionen des zentralen Nervensystems zu unterstützen // Vierte FDA-Zulassung in 2024 markiert... ► Artikel lesen | |
BIONTECH | 99,40 | -1,78 % | Ihre wichtigsten Termine: Heute: Q-Zahlen von Ryanair, Biontech, Marriott International und Altice USA | © Foto: Julian Stratenschulte - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
BEAM THERAPEUTICS | 26,630 | +11,28 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,79 | +0,23 % | Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal | ||
ARCELLX | 92,94 | +6,68 % | Navigating 7 Analyst Ratings For Arcellx | ||
TARSUS PHARMACEUTICALS | 46,790 | +2,47 % | Tarsus Pharmaceuticals, Inc: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer | IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize... ► Artikel lesen | |
ADMA BIOLOGICS | 19,690 | +4,79 % | Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings? | ||
PRAXIS PRECISION MEDICINES | 72,08 | -0,89 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 47,290 | +4,86 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) | SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 10,160 | +5,39 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,890 | +2,45 % | Why Summit Therapeutics Stock Was a Winner Today | ||
SPRINGWORKS THERAPEUTICS | 33,000 | +4,46 % | SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | - PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks... ► Artikel lesen | |
BB BIOTECH | 40,150 | +2,95 % | BB Biotech Aktie: Weiterhin auf Erfolgskurs! | Die BB Biotech-Aktie verzeichnete am 1. November 2024 einen beachtlichen Kurssprung auf 39,85 EUR und überschritt damit die bedeutsame 50-Tage-Linie. Diese positive Entwicklung deutet auf ein gesteigertes... ► Artikel lesen | |
KEROS THERAPEUTICS | 66,35 | +6,02 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results |